Nov 01, 2018 9:03 am EDT Atara Biotherapeutics Announces Presentations Highlighting Robust Off-the-Shelf, Allogeneic T-Cell Immunotherapy Pipeline and Next-Generation CAR T Technologies at the 60th American Society of Hematology (ASH) Annual Meeting and European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2018
Sep 24, 2018 4:55 pm EDT Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 11, 2018 8:00 am EDT Atara Biotherapeutics Appoints Cancer Research and Clinical Development Veteran, Roy Baynes, to its Board of Directors
Sep 06, 2018 7:30 am EDT Atara Biotherapeutics and Moffitt Cancer Center Announce Strategic Collaboration to Develop Next-Generation CAR T Immunotherapies
Aug 06, 2018 4:50 pm EDT Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 01, 2018 8:00 am EDT Atara Biotherapeutics Announces Second Quarter 2018 Financial Results and Recent Operational Progress
Jul 31, 2018 4:45 pm EDT Atara Biotherapeutics to Participate in the Canaccord Genuity 38th Annual Growth Conference
Jun 25, 2018 8:00 am EDT Atara Biotherapeutics Opens State-of-the-Art Operations and Manufacturing Facility to Support Robust Off-the-Shelf T-Cell Immunotherapy Pipeline
Jun 15, 2018 2:30 am EDT Atara Biotherapeutics’ Tab-cel™ Achieves Positive Long-Term Outcomes in Phase 2 Studies of Patients with Epstein-Barr Virus Associated Post-Transplant Lymphomas